UB639
TargetsAPOC3
IndicationsFamilial chylomicronemia syndrome; Severe hypertriglyceridemia; Dyslipidemia
ClinicalCN - I
TherapeuticsCardiovascular
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- • Global BIC APOC3-siRNA with superior Potency and durability at low dose.
- • Excellent APOC3-siRNA data from ongoing Ph 1 trial: superior efficacy and long-lasting effect with yearly-dosing potential (vs Plozasiran Q3M).
- • No traditional DDI concern with combination usage of small molecules.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →